tradingkey.logo

Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial Of Mr-142 In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

ReutersJun 2, 2025 12:19 PM

- Viatris Inc VTRS.O:

  • VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 LYNX-2 TRIAL OF MR-142 IN KERATOREFRACTIVE PATIENTS WITH VISUAL DISTURBANCES UNDER MESOPIC, LOW-CONTRAST CONDITIONS

  • VIATRIS INC - MR-142 ACHIEVED PRIMARY ENDPOINT OF ≥15-LETTER GAIN IN MLCVA

  • VIATRIS INC - NO EVIDENCE OF TACHYPHYLAXIS OBSERVED OVER 6-WEEK PERIOD

  • VIATRIS INC - RESULTS SHOW FUNCTIONAL BENEFIT IN TREATING NIGHT DRIVING IMPAIRMENT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI